ARTICLE SUMMARY:
Continuing our series on remote patient monitoring, we take a closer look at what one multinational medtech—Philips—is doing to boost its RPM product portfolio to meet the evolving needs of providers. The company has been active in digital health for years, but recent moves, including a partnership with RPM start-up BioIntelliSense and the launch of several of its own new RPM products, will enable Philips to address a wider range of remote care needs in both the home and hospital.
The COVID-19 pandemic has, by necessity, catapulted the telemedicine and remote patient monitoring (RPM) markets to new heights, elevating remote healthcare and digital health technologies to unprecedented levels of acceptance and adoption. With a growing number of US patients, providers, and insurers now embracing remote care options, including home-based monitoring technologies and services, many medtech companies are either looking for a way into this growing market opportunity—or for those already competing in the space, are seeking to bolster their current RPM product portfolio—through partnerships, acquisition, and/or in-house R&D.
